62 results about "Neutrophilic Granulocyte" patented technology

Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of the human G-CSF native sequence and analogues thereof. These novel site-specific mono-conjugated derivatives are recommended for therapeutic use since they are stable in solution and exhibit significant biological activity in vitro and a longer bloodstream half-life, as compared to the non-conjugated protein, with a consequent prolonged pharmacological activity.

The invention disclosed herein relates to compositions and methods for treating subjects suffering from or at risk of developing neutropenia. In some embodiments, the methods comprise administering to a subject suffering from or at risk of developing neutropenia, an effective amount of pirfenidone and one or more toll-like receptor (TLR) agonists.

The invention relates to the technical field of medicines, and relates to adriamycin-indocyanine green bionic nanoparticles coated with platelet and neutrophil fusion membranes and an application of the adriamycin-indocyanine green bionic nanoparticles in preparation of medicines for treating tumor metastasis diseases. The bionic nanoparticle coated with the platelet and neutrophil hybrid membranecomprises adriamycin, indocyanine green, a nano carrier material, a platelet membrane and a neutrophil hybrid membrane, which is characterized by comprising the following components in percentage byweight: 8 to 10 percent of doxorubicin, 8 to 10 percent of indocyanine green, 30 to 40 percent of nano carrier material and the balance of platelet and neutrophile granulocyte hybrid membrane. The bionic nanoparticle has the capability of simultaneously capturing and removing circulating tumor cells and tumor-derived exosomes through a high-affinity membrane adhesion receptor, and effectively cutsoff the relationship between the exosomes and immune cells. The primary tumor can be completely ablated, and breast cancer metastasis can be efficiently inhibited in xenograft and in-situ breast tumor models.

The invention discloses a preparation method of an edible and medicinal fungus nanofilm. The preparation method comprises steps of slant culture, seed culture, amplification culture, and producing of a nano material. The nanofilm can be directly synthesized by microorganisms, has uniform structure, controllable appearance, and short synthesis cycle, and is applicable to expanded production. The fungus nanofilm comprises beta-glucan and chitin, wherein beta-glucan can comprehensively activate the immune system of human bodies, activate macrophage and neutrophilic granulocyte, resist diseases caused by microorganisms, and activate the nonspecific immunity of a host for curing tumours, infectious diseases and wounds, and chitin also has good antibacterial effects. The edible and medicinal fungus nanofilm has good hygroscopicity and breathability, can resist bacteria, diminish inflammation and promote wound healing, can be used as artificial skin, is degradable naturally, and has an obvious three-dimensional space net structure, so that the fungus nanofilm can be combined with drugs to be used as sustained-release materials to be applicable to fields such as health care and the like.

Disclosed are an inflammation-targeted neutrophil granulocyte drug delivery system and use thereof, wherein the drug delivery system includes neutrophil granulocytes and a therapeutic substance or a detectable substance loaded into the neutrophil granulocytes or onto the surface of the neutrophil granulocytes in a direct or indirect way. By using the neutrophil granulocytes as a carrier of a drug, the drug is actively targeted to an inflammatory site, thereby increasing the drug concentration at the inflammatory site. Under the stimulation of cytokines, the neutrophil granulocytes arriving at the inflammatory site are abnormally activated, disintegrate rapidly, and die in the way of “Neutrophil extracellular traps (NETs)”. This helps to rapidly release the loaded drug to the targeted site, so as to improve the therapeutic effect and reduce the toxic and side effects.

The invention discloses a shikimic acid used for the new usage of preparing the medicine for treating ulcerative colitis. By utilizing rat ethanoic acid colitis model, the function of shikimic acid for treating ulcerative colitis is inspected, and the shikimic acid is found to have the function of effectively improving the symptoms such as rat diarrhoea, bloody stool, weight lose and colon histomorphology change; the shikimic acid has scavenging action on neutrophilic granulocyte of colonic structure, can obviously reduce the content of MDA and NO in the rat colonic structure of colonitis and the activity of T-NOS and iNOS, and enhance the level of SOD. Therefore, the shikimic acid can be used for preparing the medicine for treating ulcerative colitis.

The invention discloses a plateau work capability assessment early-warning index system. The system takes oxyhemoglobin saturation, homocysteine, blood urea and a blood neutrophilic granulocyte percentage as assessment indexes. The system detects the oxyhemoglobin saturation of a subject, acquires a blood sample of the subject, processes the acquired blood sample, and then detects the homocysteine, blood urea and blood neutrophilic granulocyte percentage of the subject. The plateau work capability of the subject is assessed and early-warned through the comparison between detection results of the oxyhemoglobin saturation, homocysteine, blood urea and blood neutrophilic granulocyte percentage of the subject and the early-warning values in the assessment index system. The plateau work capability assessment and early-warning index system can provide scientific early-warning and real-time assessment for the work capability of a plateau worker before and after working, so that proper control measures can be adopted when necessary to protect the plateau worker to the largest extent.

The invention discloses a reagent for classifying leukocytes, which can be used for classifying leukocytes into five groups corresponding to lymphocytes, monocytes, eosinophilic granulocytes, neutrophilic granulocytes and basophilic granulocytes. The reagent comprises a buffering agent and a hemolytic agent, wherein the hemolytic agent comprises at least two types of betaine type amphoteric surfactants. The reagent can be applied in wide pH value and temperature ranges, does not damage the leukocytes and can be used for accurately classifying white blood cells.

The invention relates to application of arctigenin in preparation of medicines for preventing and treating bone marrow suppression. The arctigenin has unexpected activities for enhancing immunity, promoting hemopoiesis and many other aspects. The animal in-vivo test proves that the arctigenin can obviously increase the quantity of leucocytes after chemotherapy, especially the quantity of neutrophilic granulocytes. Thus, the arctigenin is an active component capable of resisting side reactions of chemotherapy and enhancing the chemotherapeutic effect of tumors, and has very important meanings for prolonging the life time of cancer patients and improving the life quality of cancer patients.

The invention discloses application of 3,4-dihydroxyl-phenyl lactic acid in preparing a medicine treating microcirculatory disturbance. Salvia Miltrorrhiza (SM) is contained in a great number of the prior Chinese medicines used to treat blood vessel diseases, and 3,4-dihydroxyl-phenyl lactic acid(DLA) is one of main active ingredients in the Salvia Miltrorrhiza. The microcirculatory disturbance is mesentery microcirculatory disturbance and is caused by ischemia / reperfusion. The invention also discloses application of the 3,4-dihydroxyl-phenyl lactic acid in preparing a medicine for preventing adhesion of white blood cells caused by the microcirculatory disturbance, a medicine for restoring adhesional white blood cells caused by the microcirculatory disturbance, a medicine for inhibiting exudation of albumin from small veins caused by the microcirculatory disturbance, a medicine for inhibiting degranulation of mast cells caused by the microcirculatory disturbance, a medicine for inhibiting expressions of adersional molecules CD11b and CD18 on neutrophilic granulocytes caused by the microcirculatory disturbance and a medicine for inhibiting generation of peroxides caused by the microcirculatory disturbance.

The disclosed vaccine employs alkyl hydrogen peroxide reductase (AhpC) or its fusion gene with neutral granular leukocyte activated protein NapA as active constituent, as well as intra-molecule external adjuvant such as bacillus coli heat-labile toxin B subunit LTB, cholera morbus toxin B subunit CTB.

The invention discloses a reagent for realizing white cell three-way classification and detecting red cells, white cells and blood platelets in animal blood by an electric-resistivity method haematocyte instrument. The reagent is prepared from diluent and a hemolytic agent, wherein the diluent is used for detecting the red cells and the blood platelets; then, the diluent is matched with the hemolytic agent for detecting the white cells; five kinds of white cells are subjected to three-way classification, and are sequentially divided into lymphocyte group, neutrophilic granulocyte, mononuclearleucocyte groups and acidophilic cell groups according to the volume size. Compared with an ordinary optical microscopic method, the method has the advantage that the result is accurate and reliable.

The invention relates to a nutritive composition which consists of resveratrol and yeast glucan and has the function of health protection. The nutritive composition overcomes the defects of poor treatment effect and toxic and side effects by adopting Western medicines for hyperglycemic and hypolipemic treatment in the prior art. The resveratrol is an important plant antitoxin and has the functions of antioxidation, prevention and treatment of cardiovascular diseases, prevention of cancer, antivirus and immunoloregulation; the yeast glucan has the functions of clearing intestine, regulating the blood sugar, reducing cholesterin, improving the immunity and so on; and when the two types of immunomodulator, namely the resveratrol and the yeast glucan, are combined and applied, Cdc42 expression is obviously improved, and the resveratrol and the yeast glucan have stronger synergism. For example, the resveratrol and the yeast glucan express obvious synergistic effect in monocytes and neutrophilic granulocytes, and three cytokines (IL-1, IL-6 and TNF-alpha) are obviously lifted; and the nutritive composition influences the restoring activity of spleen cells and fluorouracil-induced leucocytopenia.

This invention relates to the preparation of neutral granulocyte antigen negative used to detect cytoplasmic antigen of neutrophilic granulocyte. It uses heparin anticoagulant method to subside erythrocyte and preserve leucocyte. Then it uses Ficoll-Hypaque gradient reagent to separate neutrophilic granulocyte. Then put in NaCl solution and it becomes cell suspension. Put the suspension directly on to the slide and a neutrophilic granulocyte antigen negative is ready. This negative's detectable rate is obviously greater than other domestic negatives. It has little difference with the import reagent and the cells has only one single deck and is evenly distributed. The result is easy to observe ,so it can meet clinic demand.

The invention provides a method for screening a phosphodiesterase (PDE) inhibitor. The method comprises the following steps of: after the reaction of extracts of the traditional Chinese medicine with the PDE sample, detecting the activity of the PDE, and judging target points with selective action for inhibiting the activity of the PDE; and judging the effective ingredients for inhibiting the PDE according to the change of finger print of the extracts of the traditional Chinese medicine, thus screening the selective phosphodiesterase inhibitor. The method comprises the steps of preparation of extracts of the traditional Chinese medicine, preparation of PDE samples, cell incubation, detection of the activity of PDE and detection of finger print of extract samples of the traditional Chinese medicine; the preparation of the PDE samples comprises preparation of PDE samples of animal tissues, preparation of PDE samples of animal skeletal muscle and preparation of PDE samples of animal neutrophilic granulocyte.

The invention relates to a method for preparing a gene therapy medicine for novel corona virus 2019. The method comprises the following steps: according to an nCoV2019 (novel corona virus 2019) genome, screening an siRNA (small interference ribonucleic acid) sequence with an RNA interference effect, and performing synthesis by using a nucleic acid synthesis method; and preparing synthesized nCoV2019siRNA into lipid nanoparticles LHNPs, and compounding LHNPs or nCoV2019siRNA with a spray, so as to obtain a gene therapy product with inhalation administration. When reaching target cells, siRNA isdegraded since an siRNA antisense strand which is generated under the action of inherent and stress boosted helicase and endonuclease / exonuclease is combined with homologous RNA and / or mRNA (messenger ribonucleic acid). In addition, type-I interferon, IL-6, TNFa (tumor necrosis factor a) and the like can be generated under stimulation of double-strand siRNA and cellular immunity can be mediated,it is known that type-I interferon has antiviral immunity, IL-6 is capable of inducing hyperplasia of immune globulin and T cells, and the TNFa is capable of promoting infection resistance of neutrophile granulocyte, inducing apoptosis of virus infected cells and thus inhibiting virus hyperplasia, so that in addition to virus prevention of RNA interference, antibacterial antiviral immunity of cellfactors, immune cells and immune globulin can be also triggered, and in addition, the medicine can be efficiently and rapidly synthesized, and is easy in short-term application to treatment or prevention.

The invention discloses an application of pulsatilla saponin B4 in preparation of a drug for treating / preventing bacterial pneumonia, induced by klebsiella pneumoniae, of mammals including human being. The pulsatilla saponin B4 has a protecting function on bacterial pneumonia induced by klebsiella pneumoniae, a protecting mechanism can be related to reduction of the content of inflammatory factorsIL-6, IL-1beta and TNF-alpha, the content of MPO, IL-6 and TNF-alpha in lung tissue and the number of neutrophile granulocyte and leukocyte in plasma, and the pulsatilla saponin B4 for injection hasa better effect than a positive drug.

The invention discloses a sanguisorba officinalis aglycone lipidosome, which is prepared from the following raw and auxiliary materials in proportion by weight: 1 part of sanguisorba officinalis aglycone and 2 to 40 parts of carrier materials, wherein the carrier materials are prepared from hydrogenated soybean phospholipids, distearoyl phosphoethanolamine-polyethyleneglycol 2000 and cholesterin according to a weight ratio of 5:(1 to 4):(1 to 2). The invention also provides a preparation method and a purpose of the lipidosome. The lipidosome has the advantages that the number of peripheral blood leucocytes, neutrophilic granulocytes, red cells, blood platelets, hemoglobin and bone marrow hematopoietic stem cells can be obviously increased; and the obvious effects of treating and / or preventing bone marrow suppression are achieved.

The invention relates to use of 1-ethyl-3, 7-dimethylxanthine in preparing a medicine for treating pneumonia and belongs to the technical field of medicines. The invention provides use of 1-ethyl-3, 7-dimethylxanthine or a salt thereof in preparing a medicine for treating pneumonia. Pharmacological experiment results show that various dosage forms of the 1-ethyl-3, 7-dimethylxanthine can obviously inhibit pneumonia caused by infection of viruses, bacteria and mycoplasmas, reduce a lung index of infected mice, reduce levels of inflammatory factors such as TNF-alpha, IL-8, IL-10 and IL-17, improve a level of IFN-gamma and improve count of leukocyte and neutrophile granulocyte in peripheral blood, which indicate that the 1-ethyl-3, 7-dimethylxanthine has a strong anti-pneumonia effect.

The invention relates to application of a compound as shown in the general formula (I) or pharmaceutically acceptable salt in the preparation of medicines for preventing and / or treating cytopenia of patents who will receive, is receiving or has received chemotherapy and drug therapy. In the general formula, R1, R2 and R3 can be the same or different and respectively and independently represent H or C1-C3 alkyl group. In comparison with common clinical drugs (such as G-CSF) for increasing haemocyte count for those who receive chemotherapy, the compound of the invention can remarkably increase hemocyte in those who receive chemotherapy, especially increase leucocyte, in particular the number of neutrophile granulocyte and monocyte. The compound of the invention has a good clinical prospect.

A neutrophil activity test method is that 1 weight portion of pyogenic bacteria inactivated vaccine is mixed evenly with 1 to 1.5 portions of medical turpentine, 0.3 to 0.5ml of the reagent is dropped in carrier medicinal cotton to be pasted on the one-inch skin of the left hand or the right hand of a human body by using an adhesive plaster, the adhesive plaster is ripped off after 12 to 24 hours of the action time of the reagent, vacuole is formed on the skin, the position of the vacuole is pasted with an adhesive plaster with indicators for 24 to 25 hours, then the adhesive plaster is uncovered to observe the fading situations. The test method is that acute suppurative inflammation is produced on the skin of the human body through an induced inflammatory method to observe the skin suppuration, detect and undergo the activity of myeloperoxidase (MPO) to judge whether the functional neutrophil (PMN) activity has defects and obstacles. The neutrophil activity test method has accuracy of more than 92 percent through the tests of 25 patients with various cancers, 23 of the 25 patients having no fading of the indicators and 2 of the 25 patients having unobvious fading reaction of the indicators, and the tests on 40 healthful human bodies with complete fading reaction of the indicators.

The invention relates to the technical field of biomedical science detection, and discloses a construction method of a living cell probe based on neutrophilic granulocyte. The construction method comprises the steps of: A, performing BSA reduction; B, synthesizing Gd loaded BSA nanoparticles; C, labeling the Gd loaded BSA nanoparticles with Bodipy; and D, constructing a neutrophilic granulocyte probe: firstly with PBS as a medium, adding DTNB to a product solution in the step C, performing interaction at room temperature for a certain time to finish activation of BSA nanoparticles, after ultrafiltration and purification are performed, diluting the activated BSA nanoparticles to 0.1mg mL<-1> with an RPMI 1640 culture medium without FBS, then performing incubation with 1.25*10<6>cells.mL<-1>of neutrophilic granulocyte at room temperature, and then performing washing with ice-cold PBS so as to obtain the neutrophilic granulocyte probe.

The invention relates to a separation method and a separation kit for neutrophil in blood, and belongs to the technical field of neutrophil separation. The invention provides the separation method for the neutrophil in blood, which comprises the following steps: sequentially adding a neutrophile granulocyte separating medium, a lymphocyte separating medium and whole blood into a centrifugal tube, enabling the lymphocyte separating medium to be positioned above the neutrophile granulocyte separating medium and the whole blood to be positioned above the lymphocyte separating medium, then centrifuging, and separating to obtain the neutrophile granulocytes. The invention further provides a separation kit for the neutrophil in the blood. The separation kit contains a neutrophil separation medium and a lymphocyte separation medium which are independently packaged respectively. By adopting the separation method or the separation kit provided by the invention, the neutrophil with the purity of about 80% can be rapidly obtained through one-time centrifugation, and the neutrophil and the red blood cells can be separated at the same time through one-time centrifugation, so that the separation method or the separation kit has a very good practical value.

The invention relates to the technical field of biological medicines, in particular relates to application of a GSDMD inhibitor in preparation of a medicine for treating helicobacter pylori infection,and aims to solve the problem that a death signalling pathway of neutrophile granulocyte after helicobacter pylori infection, in particular change of pyroptosis molecular mechanism, is unclear in theprior art. After the signalling pathway is definite, the condition that stomach helicobacter pylori infection can be treated by utilization of the GSDMD inhibitor can be prompted; the pyroptosis process of the neutrophile granulocyte infiltrated at the infection part is inhibited; therefore, the clinical existing antibacterial medicine combined therapy is replaced; and generation of the medicinetolerance is reduced.

This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The present invention relates to a mutant G-CSF fusion protein. The mutant G-CSF fusion protein is a fusion protein having the activity of stimulating the proliferation of neutrophilic granulocytes, and having a basic structure of G-CSF / carrier protein or carrier protein / G-CSF; wherein the G-CSF moiety comprises multipoint substitutions thus resulting in changes in biological activity and binding affinity. Compared with existing products, the mutant G-CSF fusion protein in the present invention has longer half-life and higher biological activity. Administration of the pharmaceutical preparation containing this mutant G-CSF fusion protein could be used in the treating neutropenia.

The invention discloses a construction method and application of a gout animal model. The construction method comprises the steps of injecting a uricase inhibitor into the abdominal cavity of a rat every day for one week to inhibit the activity of uricase of the rat and meanwhile injecting uric acid salt crystals and ATP into the tail vein to make the rat spontaneously develop gouty arthritis. Theprovided construction method of the gout animal model can stably and rapidly induce gout in the rat, and the clinical manifestation and pathological characteristics of the model are completely matched with the characteristics of human gout. According to the gout model constructed by means of the method, massive uric acid salt crystals can be observed under a polarizing microscope in a diseased joint, and infiltration of massive neutrophilic granulocytes can be found through immunohistochemistry. In addition, the invention also relates to the application of the gout animal model constructed bymeans of the method in research on the occurrence and remission mechanisms of gout and related inflammation, screening and evaluation of therapeutic drugs and the like.

The invention belongs to the technical field of medicine and particularly relates to an application of nevirapine in preparing medicine for preventing and treating inflammation related diseases. Inflammation is aseptic inflammation and immune inflammation. The application of nevirapine in preparing the anti-inflammatory medicine is disclosed for the first time. Through experiment research on a copper sulfate induced zebra fish inflammation model, the result shows that nevirapine can promote degradation of neutrophile granulocyte of inflammatory sites and has anti-inflammatory and inflammation diminishing effects. Thus, nevirapine has the obvious anti-inflammatory effect on the inflammation related diseases and can be used for preparing the medicine for preventing and treating the inflammation related diseases.